Eton Pharmaceuticals, Inc. — Director's Dealing 2022

Apr 14, 2022

SEC Form 3 — Initial Statement of Beneficial Ownership

Issuer: Eton Pharmaceuticals, Inc. (ETON)
CIK: 0001710340
Period of Report: 2022-04-11

Reporting Person: Gruber James R. (Chief Financial Officer)

Holdings (Derivative)

Security	Exercise Price	Expiration	Underlying	Shares	Ownership
Employee Stock Options	$3.81	2032-04-10	Common Stock (100000)		Direct

Footnotes

F1: Stock options awarded on April 11, 2022 to Reporting Person pursuant to the Company's 2018 Equity Incentive Plan (the "Plan"). The stock options vest contingent upon continued employment as follows: 25, 000 on April 11, 2023, 25,000 on April 11, 2024, 25,000 on April 11, 2025 and 25,000 on April 11, 2026.